Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeronMIL:1GERN 20 EV-to-EBIT is -21.96 as of Aug. 21, 2026. GuruFocus rates MIL:1GERN with a GF Score™ of 20/100 and a GF Value™ of €6.00 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 373 Biotechnology companies, Geron ranks worse than 268096.25% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Geron's Enterprise Value is €702.8 Mil.
Geron's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-32.0 Mil. Therefore, Geron's EV-to-EBIT for today is -21.96.
The historical rank and industry rank for Geron's EV-to-EBIT or its related term are showing as below:
MIL:1GERN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -30.29 Med: -6.3 Max: 260.71
Current: -21.95
During the past 13 years, the highest EV-to-EBIT of Geron was 260.71. The lowest was -30.29. And the median was -6.30.
MIL:1GERN's EV-to-EBIT is ranked worse than 100% of 373
companies
in the Biotechnology industry
Industry Median: 15.29
vs MIL:1GERN: -21.95
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Geron's Enterprise Value for the quarter that ended in Jun. 2026 was €573.1 Mil.
Geron's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-32.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron EV-to-EBIT Related Terms
Geron EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Geron's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1GERN vs PHAT, KURA, ODTX: EV-to-EBIT Comparison
For the Biotechnology subindustry, Geron's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Geron's EV-to-EBIT falls into.
Geron's current Enterprise Value is €702.8 Mil.
Geron's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-32.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron (MIL:1GERN) has a EV-to-EBIT of -21.96 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Geron and its competitors. According to the industry distribution chart, Geron ranks #999999 out of 373 companies in the Biotechnology industry.
Is Geron's EV-to-EBIT too high?
Geron's current EV-to-EBIT is -21.96. Based on the distribution chart, Geron ranks #999999 out of 373 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Geron has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's EV-to-EBIT compare to PHAT and KURA?
According to the Biotechnology industry distribution chart, Geron ranks #999999 out of 373 companies for EV-to-EBIT. This places Geron in the lower half of its industry. The industry median EV-to-EBIT is 15.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.29, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Geron and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current EV-to-EBIT is -21.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (MIL:1GERN) is currently considered Possible Value Trap. The stock's GF Value™ is €6.00, compared to a current price of €1.30 — trading 78.4% below its estimated fair value. The current EV-to-EBIT is -21.96. Geron's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Geron (MIL:1GERN), the current EV-to-EBIT is -21.96 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (MIL:1GERN) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.30 is trading 78.4% below its estimated GF Value™ of €6.00.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for MIL:1GERN:
EV-to-EBIT: -21.96
GF Value™: €6.00 vs. price of €1.30 (78.4% below fair value)
No single metric tells the full story. See the MIL:1GERN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
20GF Score
Get the complete analysis for MIL:1GERN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1GERN has been successfully added to your 
